Apollo Hospitals Enterprise Limited

rs,

8035 12th August 2025 The Secretary, Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 508869 ISIN INE437 A01024 Dear Sir, 'G' Block

11%

Revenue Growth YoY(%) EBITDA(Post Ind AS) Margin Growth YoY(%) Healthcare Services 29,351 11% 7,179 24.5% 15% PAT 3,840 Growth YoY(%) 13.1% 17% o C h t l a e H o l l o p A Offlin

24.5%

th YoY(%) EBITDA(Post Ind AS) Margin Growth YoY(%) Healthcare Services 29,351 11% 7,179 24.5% 15% PAT 3,840 Growth YoY(%) 13.1% 17% o C h t l a e H o l l o p A Offline PD ^ 21,634

15%

(%) EBITDA(Post Ind AS) Margin Growth YoY(%) Healthcare Services 29,351 11% 7,179 24.5% 15% PAT 3,840 Growth YoY(%) 13.1% 17% o C h t l a e H o l l o p A Offline PD ^ 21,634 18%

13.1%

Growth YoY(%) Healthcare Services 29,351 11% 7,179 24.5% 15% PAT 3,840 Growth YoY(%) 13.1% 17% o C h t l a e H o l l o p A Offline PD ^ 21,634 18% 1,669 7.7% 20% Online PD^ & 2

17%

YoY(%) Healthcare Services 29,351 11% 7,179 24.5% 15% PAT 3,840 Growth YoY(%) 13.1% 17% o C h t l a e H o l l o p A Offline PD ^ 21,634 18% 1,669 7.7% 20% Online PD^ & 24|7

18%

15% PAT 3,840 Growth YoY(%) 13.1% 17% o C h t l a e H o l l o p A Offline PD ^ 21,634 18% 1,669 7.7% 20% Online PD^ & 24|7 3,085 26% (732) Vs (1,163) in Q1F25 Total HealthCo 2

7.7%

40 Growth YoY(%) 13.1% 17% o C h t l a e H o l l o p A Offline PD ^ 21,634 18% 1,669 7.7% 20% Online PD^ & 24|7 3,085 26% (732) Vs (1,163) in Q1F25 Total HealthCo 24,718 19% 9

20%

rowth YoY(%) 13.1% 17% o C h t l a e H o l l o p A Offline PD ^ 21,634 18% 1,669 7.7% 20% Online PD^ & 24|7 3,085 26% (732) Vs (1,163) in Q1F25 Total HealthCo 24,718 19% 938

26%

l a e H o l l o p A Offline PD ^ 21,634 18% 1,669 7.7% 20% Online PD^ & 24|7 3,085 26% (732) Vs (1,163) in Q1F25 Total HealthCo 24,718 19% 938 3.8% 569 2.3% AHLL 4,351 19

19%

7.7% 20% Online PD^ & 24|7 3,085 26% (732) Vs (1,163) in Q1F25 Total HealthCo 24,718 19% 938 3.8% 569 2.3% AHLL 4,351 19% 403 9.3% 31% (80) Consolidated 58,421 15% 8,51

3.8%

Online PD^ & 24|7 3,085 26% (732) Vs (1,163) in Q1F25 Total HealthCo 24,718 19% 938 3.8% 569 2.3% AHLL 4,351 19% 403 9.3% 31% (80) Consolidated 58,421 15% 8,519 14.6% 2

“Tel Telefax Email Website : www.apollohospitals.com : 044 - 2829 0956 I 3896 I 6681 : 044 - 2829 0956 : investor.relations@apollohospitals.com Apollo Hospitals Enterprise Limited Earnings Update Q1 FY26 • Disclaimer The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference.”

“You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.”

“• Private and Generic Label sales at 15.8% (offline) for Q1 FY26.”

“in Q1FY26, growth of 23% over Q1 FY25 Full stack digital healthcare platform • First-in-class AI enabled technologies including India’s first Clinical Intelligence Engine • Provides comprehensive remote healthcare services.”

“' Clinics il),A ® Apollo Sugar Clinics  Core revenues of Primary Care grew by ~17% YoY in Q1 FY26, as a result of revamped health check plans and strengthening of corporate outreach  Preventive Health-checks volume grew by ~46% YoY in Q1 FY26  Rolled out an integrated obesity management program, expanding the service portfolio  1 New Clinic & 8 New Dialysis Centres launched in Q1 FY26 ~.A Apollo DIAGNOSTICS ®  New state-of-the-art Digi-Smart Central Reference Laboratory (~45k sq.”

“ft.) launched in Chennai – Combined with existing GRL in Hyderabad, it will result in processing capacity of 1.5 lakh samples/day  Net addition of 5 Satellite Labs & 65 Collection Centers to the network  Wellness segment volume grew by ~34% YoY in Q1 FY26 & accounted ~20% of Diagnostics revenue (vs ~18% in FY24)  Test-menu expansion to cover Couple Karyotyping, Carrier Screening by CES, Fragile X Syndrome, HOMA-IR, TSH Receptor Antibodies, 5G Genotyping etc.”

“il)A e Apollo Soectra Specialists IHOSPITALS in Surgery ~lo Cradle &Children's Hospital ltollo Fertility  Spectra: ~9% YoY revenue growth in Q1 FY26 driven by operationalization of renovated Jaipur center  Cradle: ~9% YoY revenue growth in Q1 FY26.”

“1 New Centre to be commissioned in Q3 FY26  Fertility: ~11% YoY revenue growth in Q1 FY26.”

“gross realization per patient (INR)2,3 Network Growth – Collection Centers Operational footprint (as of June 30, 2025) ~330+ ~330+ ~330+ Cities Cities presence Cities presence presence 108 Labs 827 806 811 822 2,263 731 15,143 13,697 16,205 14,420 14,898 717 20,820 2,330 -90 2,221 2,100+ Collection Centres 2,173 2,102 2,108 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Footfalls / Day** Gross ARPV (Rs.) 1.”

“129 Mn in Q1’FY25 on account of growth in operational revenue and optimization of 247 operating cost partially getting offset by increase in non cash charge item (ESOP)”

Regd. Office

1

General Office

1

Omnichannel Healthcare Division

1

Digital Operational Metrics

1

General Office

"Ali Towers" Ill Floor, #55, Greams Road, Chennai - 600 006. Tel Telefax Email Website : www.apollohospitals.com : 044 - 2829 0956 I 3896 I 6681 : 044 - 2829 0956 : investor.relations@apollohospitals.com Apollo Hospitals Enterprise Limited Earnings Update Q1 FY26 • Disclaimer The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expres

Omnichannel Healthcare Division

o Omnichannel Pharmacy (AHL+ APL) Business revenue of Rs 31,640 Mn in Q1’ FY26 compared to a revenue of Rs. 26,148 Mn in Q1’ FY25 (growth of 21%). o Apollo Telehealth (under AHEL)- While Revenues remain stagnant ( Rs.183 Mn in Q1FY26 vs 186 Mn in Q1 FY25), there is positive movement in EBITDA (14.1 Mn in Q1FY26 vs 1.4 Mn in Q1 FY25).

Digital Operational Metrics

o Platform GMV : Rs 6,825 Mn in Q1’ FY26, growth of 23% over Q1’ FY25 (5,532 Mn) o New customer acquisition channel started to gain traction (launch of 19 mins & Omni Acquisition) o Continuous Improvement in quantitative parameters in Q1’ FY26 vs Q1’ FY25: o 42% YoY growth in Online Pharma Transactions o 36% YoY growth in Transacting users. Offline Segment o 14% YoY growth in offline transactions (8.0 cr Vs 7.0 cr year back) 50% Q1'FY25 Q4'FY25 Q1'FY26 o Serving ~8.8 lac offline customers per day *Cash loss/profit is EBITDA post Ind As excluding ESOP expense © 2025 Apollo Hospitals Enterprise Ltd, All Rights Reserved 28 ` MioOffline Pharmacy Distribution Online Pharmacy Distribution & Apollo 247Total HealthCoTotal Revenues21,6343,08524,718EBITDA (Pre 24|7 Cost)1,6694762,145margin (%) 7.7%15.4%8.7%24/7 Operating Cost-963-963ESOP(Non Cash expense)-245-245EBITDA 1,669-732938margin (%) 7.7%-3.8%EBIT692PBT571PAT (Reported)571Total Revenues18,3692,45220,821EBITDA (Pre 24|7 Cost)1,3883341,721